Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Operating Income: 2011-2025

Historic Operating Income for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $51.0 million.

  • Adma Biologics' Operating Income rose 28.69% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $167.0 million, marking a year-over-year increase of 45.36%. This contributed to the annual value of $139.0 million for FY2024, which is 542.49% up from last year.
  • As of Q3 2025, Adma Biologics' Operating Income stood at $51.0 million, which was up 19.19% from $42.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Operating Income ranged from a high of $51.0 million in Q3 2025 and a low of -$15.6 million during Q2 2021.
  • For the 3-year period, Adma Biologics' Operating Income averaged around $26.3 million, with its median value being $34.9 million (2025).
  • As far as peak fluctuations go, Adma Biologics' Operating Income decreased by 4.61% in 2021, and later surged by 8,387.74% in 2024.
  • Quarterly analysis of 5 years shows Adma Biologics' Operating Income stood at -$13.2 million in 2021, then surged by 54.07% to -$6.1 million in 2022, then surged by 334.93% to $14.2 million in 2023, then surged by 169.25% to $38.3 million in 2024, then grew by 28.69% to $51.0 million in 2025.
  • Its Operating Income was $51.0 million in Q3 2025, compared to $42.8 million in Q2 2025 and $34.9 million in Q1 2025.